ReviewEuropean cytokine network2026
Cytokine signalling in vaginal epithelial cells: mechanistic insights into epithelial immunity and inflammatory milieu in vulvovaginal candidiasis.
Review in European cytokine network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Vulvovaginal candidiasis (VVC) is one of the most prevalent mucosal infections worldwide, experienced by women throughout their reproductive years. Candida albicans is involved in 85-95% of all VVC cases and given the stronger correlation between the severity of epithelial cytokine responses, rather than fungal burden, with VVC symptoms, this disease is fundamentally immunopathological. VVC is believed to be initiated by a cascade of events that leads to vaginal epithelial cell (VEC) damage. These cells act as immune sentinels and can detect fungal morphotypes as well as virulence factors through diverse pattern recognition receptors, such as TLRs, C-type lectin receptors, and nucleotide-binding oligomerization domain-like receptors. Recognition of C. albicans can trigger complex intracellular signalling cascades in VECs that involve NF-κB, MAPK, and activator protein-1, which culminate in robust production of proinflammatory cytokines, chemokines, and alarmins. The hypha-specific peptide toxin, candidalysin can also initiate VEC membrane damage, which leads to nucleotide-binding oligomerization domain, leucine-rich repeat family and pyrin domain-containing protein 3 inflammasome assembly in the VECs. The resulting inflammatory events lead to robust recruitment of neutrophils, which, although they fail to effectively clear the fungus, add to even more tissue damage, contributing to the severity of VVC symptoms. This review synthesises the molecular- and cellular-based evidence to clarify the role of VEC-related immune activation in the development of VVC and to provide a new understanding that VVC signs and symptoms are predominantly immune-related.
Indexed as
Identifiers
42421499What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.